Compare Johnson & Johnson (JNJ) vs Altria Group Inc (MO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Altria Group Inc — how do they compare? Johnson & Johnson trades at $250.83 (market cap $598.96B), while Altria Group Inc trades at $73.24 (market cap $124.67B). The key difference: Johnson & Johnson is far larger — about 4.8× Altria Group Inc's market cap, and Altria Group Inc pays the higher dividend (5.68%). Which is the better fit depends on your goals.
| JNJ | MO | |
|---|---|---|
Market Cap | $598.96B | $124.67B |
Volume | 6,156,228 | — |
Sector | Health | Consumer Staples |
52-Week High | $267.24 | $74.66 |
52-Week Low | $164.36 | $54.72 |
Enterprise Value | $631.90B | $145.75B |
Dividend Yield | 2.15% | 5.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $250.61, down 0.96% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $2.90 versus $2.84 expected, and revenue growth of 6.6% year-over-year. The stock shows robust profitability with a net income margin of 21.48% and ROE of 26.42%, supported by consistent dividend payments including the recent $1.34 per share declared for H1-2026.
JNJ presents a favorable investment case with analyst consensus price target of $279.33 implying ~11% upside, though rising debt-to-asset ratio to 24.06% in 2025 and volatile cash flow trends pose risks. The healthcare giant's diversified portfolio and raised full-year guidance underpin long-term stability, but investors should monitor execution amid competitive and regulatory pressures.
Altria Group (MO) trades at $72.99, down 1.64% on the day, with a P/E of 15.59 and strong net income margin of 39.52%. Recent earnings show mixed results, beating estimates in Q1 2026 but missing in Q4 2025. Technical indicators suggest a bullish trend with support at $73 and resistance at $75. The company maintains robust cash flow from operations at $9.29B and declared a $1.06 dividend payable in July 2026.
MO offers a high dividend yield and stable cash flows, appealing for income investors, but faces risks from declining smoking trends and regulatory pressures. Analyst consensus is bullish with a $71 price target, though revenue stagnation and debt levels warrant caution. The stock's defensive qualities provide stability amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →
